FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384652197> ?p ?o ?g. }

• W4384652197 endingPage "e006694" @default.
• W4384652197 startingPage "e006694" @default.
• W4384652197 abstract "Background Expression of immune checkpoints in the tumor microenvironment is one mechanism underlying paclitaxel (PTX) chemoresistance. This study aimed to investigate whether the addition of checkpoint blockade to PTX can improve the therapeutic efficacy against apparently disseminated intraperitoneal tumors. Methods We analyzed the in vivo expression of various immune checkpoints in CD3 + CD8 + cytotoxic T cells from tumor-bearing mice treated with or without PTX and validated the tumor-killing activities of selected checkpoint-expressing T-cell subpopulations ex vivo. The regulation of selected checkpoints was investigated in vitro. The therapeutic effects of inhibition of a targeted checkpoint pathway with antibodies added to PTX therapy were examined. Results CD3 + CD8 + T cells expressed with herpes virus entry mediator (HVEM), programmed cell death 1 (PD-1), and T-cell immunoglobulin domain and mucin domain 3 (TIM-3) in tumor-bearing hosts treated with PTX had effective tumoricidal activities. In addition to PTX and cytokines, B and T lymphocyte attenuator (BTLA) or homologous to lymphotoxin, exhibits inducible expression and competes with herpes simplex virus (HSV) glycoprotein D for binding to HVEM, a receptor expressed on T lymphocytes (LIGHT) interacting with HVEM can regulate the expression of PD-1 on CD3 + CD8 + T cells. Interleukin (IL)-15 increased the percentage of HVEM high granzyme B (GZMB) + cells among CD3 + CD8 + T cells, which was suppressed by the BTLA/HVEM signal. LIGHT induced the percentage of HVEM + GZMB + cells but not HVEM high GZMB + cells among CD3 + CD8 + T cells. Expression of IL-15, BTLA, or LIGHT was detected in CD19 + B cells and regulated by damage-associated molecular patterns/Toll-like receptor interactions. In the tumor-bearing hosts treated with PTX, certain proportions of BTLA + B or PD-1 + T lymphocytes were still noted. When dual inhibition of BTLA and PD-1 was added to PTX, the antitumor effects on intraperitoneally disseminated tumors can be significantly improved. Conclusions Dual blockade of BTLA on B cells and PD-1 on cytotoxic T cells may have clinical potential for enhancing the efficacy of PTX in the treatment of tumors with intraperitoneal spread, including epithelial ovarian carcinomas." @default.
• W4384652197 created "2023-07-19" @default.
• W4384652197 creator A5010579083 @default.
• W4384652197 creator A5022540715 @default.
• W4384652197 creator A5026435150 @default.
• W4384652197 creator A5045726763 @default.
• W4384652197 creator A5049874307 @default.
• W4384652197 creator A5067294591 @default.
• W4384652197 creator A5075304558 @default.
• W4384652197 creator A5087625198 @default.
• W4384652197 date "2023-07-01" @default.
• W4384652197 modified "2023-10-18" @default.
• W4384652197 title "Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors" @default.
• W4384652197 cites W1516464304 @default.
• W4384652197 cites W1798290921 @default.
• W4384652197 cites W1971821333 @default.
• W4384652197 cites W1977099733 @default.
• W4384652197 cites W1977177808 @default.
• W4384652197 cites W1981431992 @default.
• W4384652197 cites W1988881559 @default.
• W4384652197 cites W1990863238 @default.
• W4384652197 cites W1998258610 @default.
• W4384652197 cites W2004630197 @default.
• W4384652197 cites W2017718094 @default.
• W4384652197 cites W2030612376 @default.
• W4384652197 cites W2040295045 @default.
• W4384652197 cites W2052855154 @default.
• W4384652197 cites W2055132644 @default.
• W4384652197 cites W2059426479 @default.
• W4384652197 cites W2062398277 @default.
• W4384652197 cites W2066671159 @default.
• W4384652197 cites W2074546881 @default.
• W4384652197 cites W2084599508 @default.
• W4384652197 cites W2106747061 @default.
• W4384652197 cites W2112197042 @default.
• W4384652197 cites W2133882399 @default.
• W4384652197 cites W2139056292 @default.
• W4384652197 cites W2182743085 @default.
• W4384652197 cites W2210453860 @default.
• W4384652197 cites W2294927533 @default.
• W4384652197 cites W2508466388 @default.
• W4384652197 cites W2560367415 @default.
• W4384652197 cites W2597613988 @default.
• W4384652197 cites W2766673373 @default.
• W4384652197 cites W2771290640 @default.
• W4384652197 cites W2788656587 @default.
• W4384652197 cites W2792067978 @default.
• W4384652197 cites W2795293588 @default.
• W4384652197 cites W2952998155 @default.
• W4384652197 cites W2966340800 @default.
• W4384652197 cites W2991016171 @default.
• W4384652197 cites W3015942924 @default.
• W4384652197 cites W3040762998 @default.
• W4384652197 cites W3156044921 @default.
• W4384652197 cites W3175481001 @default.
• W4384652197 cites W3196985515 @default.
• W4384652197 cites W4281395582 @default.
• W4384652197 doi "https://doi.org/10.1136/jitc-2023-006694" @default.
• W4384652197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37463789" @default.
• W4384652197 hasPublicationYear "2023" @default.
• W4384652197 type Work @default.
• W4384652197 citedByCount "0" @default.
• W4384652197 crossrefType "journal-article" @default.
• W4384652197 hasAuthorship W4384652197A5010579083 @default.
• W4384652197 hasAuthorship W4384652197A5022540715 @default.
• W4384652197 hasAuthorship W4384652197A5026435150 @default.
• W4384652197 hasAuthorship W4384652197A5045726763 @default.
• W4384652197 hasAuthorship W4384652197A5049874307 @default.
• W4384652197 hasAuthorship W4384652197A5067294591 @default.
• W4384652197 hasAuthorship W4384652197A5075304558 @default.
• W4384652197 hasAuthorship W4384652197A5087625198 @default.
• W4384652197 hasBestOaLocation W43846521971 @default.
• W4384652197 hasConcept C148125776 @default.
• W4384652197 hasConcept C154317977 @default.
• W4384652197 hasConcept C167672396 @default.
• W4384652197 hasConcept C202751555 @default.
• W4384652197 hasConcept C203014093 @default.
• W4384652197 hasConcept C2776090121 @default.
• W4384652197 hasConcept C2777701055 @default.
• W4384652197 hasConcept C2780237676 @default.
• W4384652197 hasConcept C2780380082 @default.
• W4384652197 hasConcept C2780851360 @default.
• W4384652197 hasConcept C502942594 @default.
• W4384652197 hasConcept C55493867 @default.
• W4384652197 hasConcept C71924100 @default.
• W4384652197 hasConcept C86803240 @default.
• W4384652197 hasConcept C8891405 @default.
• W4384652197 hasConceptScore W4384652197C148125776 @default.
• W4384652197 hasConceptScore W4384652197C154317977 @default.
• W4384652197 hasConceptScore W4384652197C167672396 @default.
• W4384652197 hasConceptScore W4384652197C202751555 @default.
• W4384652197 hasConceptScore W4384652197C203014093 @default.
• W4384652197 hasConceptScore W4384652197C2776090121 @default.
• W4384652197 hasConceptScore W4384652197C2777701055 @default.
• W4384652197 hasConceptScore W4384652197C2780237676 @default.
• W4384652197 hasConceptScore W4384652197C2780380082 @default.
• W4384652197 hasConceptScore W4384652197C2780851360 @default.
• W4384652197 hasConceptScore W4384652197C502942594 @default.

• next